Purpose:
To report the successful use of tofacitinib in the treatment of refractory uveitis and scleritis.
Observations:
Two patients, one with scleritis and another with anterior and intermediate uveitis, presented with refractory disease after failure of multiple steroid- sparing therapies. Treatment with tofacitinib led to durable resolution of uveitis and scleritis.
Conclusions and importance:
Tofacitinib is a potential novel treatment option for refractory, noninfectious
Inflammatory eye disease.